drug_name event_name drug_id event_id drug_and_event_name
4 Morphine Cataract 1110410 375545 Morphine & Cataract 
## Chronograph ##

## Basic demographioc table##
1: DEC cohort n Percentage 2: Drug cohort n Percentage 3: Event cohort n Percentage 4: All drugs cohort n Percentage
Total 359 100 Total 1000 100 Total 1000 100 Total 1000 100
Sex gender = FEMALE 200 56 Sex gender = FEMALE 570 57 Sex gender = FEMALE 552 55 Sex gender = FEMALE 575 58
gender = MALE 159 44 gender = MALE 430 43 gender = MALE 448 45 gender = MALE 425 42
Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0
(20,30] 3 1 (20,30] 6 1 (20,30] 6 1 (20,30] 5 0
(30,40] 10 3 (30,40] 21 2 (30,40] 9 1 (30,40] 18 2
(40,50] 8 2 (40,50] 50 5 (40,50] 33 3 (40,50] 39 4
(50,60] 25 7 (50,60] 80 8 (50,60] 52 5 (50,60] 62 6
(60,70] 90 25 (60,70] 216 22 (60,70] 251 25 (60,70] 242 24
(70,80] 122 34 (70,80] 347 35 (70,80] 354 35 (70,80] 356 36
(80,90] 81 23 (80,90] 226 23 (80,90] 254 25 (80,90] 227 23
(90,110] 20 6 (90,110] 54 5 (90,110] 41 4 (90,110] 51 5
Median 74 IQR=(68, 81) Median 74 IQR=(67, 82) Median 75 IQR=(68, 82) Median 74 IQR=(68, 81) 
## Gender distribution ##
## DEC vs. drug ##
Characteristic % (n = 359) % (n = 1,000) Std.Diff Characteristic % (n = 359) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 1.4 1.6 0.02
25 - 29 0.8 0.5 -0.04 Visual system disorder 50.7 34.1 -0.34
30 - 34 0.3 0.5 0.04 Medical history: Cardiovascular disease
35 - 39 1.9 1.4 -0.04 Atrial fibrillation 46.0 30.4 -0.32
40 - 44 0.6 1.4 0.09 Cerebrovascular disease 14.8 12.2 -0.08
45 - 49 1.7 2.9 0.08 Coronary arteriosclerosis 47.4 37.6 -0.20
50 - 54 2.5 3.5 0.06 Heart disease 82.5 67.1 -0.36
55 - 59 3.3 4.9 0.08 Heart failure 37.6 28.7 -0.19
60 - 64 5.3 3.8 -0.07 Ischemic heart disease 20.6 16.9 -0.10
65 - 69 14.8 13.4 -0.04 Peripheral vascular disease 42.6 35.4 -0.15
70 - 74 19.8 18.2 -0.04 Pulmonary embolism 5.6 2.8 -0.14
75 - 79 17.8 17.1 -0.02 Venous thrombosis 10.9 6.6 -0.15
80 - 84 14.5 14.6 0.00 Medical history: Neoplasms
85 - 89 9.7 10.8 0.03 Hematologic neoplasm 14.8 11.5 -0.10
90 - 94 4.5 4.2 -0.01 Malignant lymphoma 8.4 5.6 -0.11
95 - 99 1.9 2.3 0.02 Malignant neoplasm of anorectum 1.1 1.3 0.02
100 - 104 0.6 0.5 -0.01 Malignant neoplastic disease 42.6 32.2 -0.22
Gender: female 55.7 57.0 0.03 Malignant tumor of breast 6.7 4.5 -0.10
Medical history: General Malignant tumor of colon 7.8 3.8 -0.17
Acute respiratory disease 32.3 22.0 -0.23 Malignant tumor of lung 5.3 4.5 -0.04
Attention deficit hyperactivity disorder 0.8 0.6 -0.03 Malignant tumor of urinary bladder 5.8 2.4 -0.17
Chronic liver disease 4.2 4.0 -0.01 Medication use
Chronic obstructive lung disease 15.9 10.6 -0.16 Agents acting on the renin-angiotensin system 59.1 61.3 0.05
Crohn’s disease 0.8 1.1 0.03 Antibacterials for systemic use 51.5 50.7 -0.02
Dementia 15.9 15.4 -0.01 Antidepressants 51.5 56.0 0.09
Depressive disorder 14.5 15.7 0.03 Antiepileptics 31.2 36.1 0.10
Diabetes mellitus 71.3 61.0 -0.22 Antiinflammatory and antirheumatic products 37.3 34.4 -0.06
Gastroesophageal reflux disease 20.9 18.7 -0.06 Antineoplastic agents 16.7 14.1 -0.07
Gastrointestinal hemorrhage 12.3 7.3 -0.17 Antipsoriatics 0.3 0.6 0.05
Human immunodeficiency virus infection 0.8 0.6 -0.03 Antithrombotic agents 49.0 48.0 -0.02
Hyperlipidemia 38.4 28.8 -0.21 Beta blocking agents 54.9 56.8 0.04
Hypertensive disorder 6.4 5.5 -0.04 Calcium channel blockers 42.9 50.9 0.16
Lesion of liver 4.7 4.9 0.01 Diuretics 59.6 64.2 0.09
Obesity 9.2 8.8 -0.01 Drugs for acid related disorders 38.2 45.9 0.16
Osteoarthritis 54.6 46.7 -0.16 Drugs for obstructive airway diseases 34.5 36.8 0.05
Pneumonia 10.3 6.6 -0.13 Drugs used in diabetes 47.9 55.0 0.14
Psoriasis 1.9 1.6 -0.03 Immunosuppressants 7.0 5.7 -0.05
Renal impairment 36.2 27.4 -0.19 Lipid modifying agents 61.6 65.1 0.07
Rheumatoid arthritis 8.6 7.8 -0.03 Opioids 30.1 33.9 0.08
Schizophrenia 7.8 7.7 0.00 Psycholeptics 53.2 55.8 0.05
Ulcerative colitis 0.6 0.6 0.01 Psychostimulants, agents used for adhd and nootropics 10.9 15.7 0.14
Urinary tract infectious disease 31.5 26.7 -0.11 
## Event vs. All ##
Characteristic % (n = 1,000) % (n = 1,000) Std.Diff Characteristic % (n = 1,000) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 1.9 1.4 -0.04
25 - 29 0.5 0.4 -0.01 Visual system disorder 47.6 30.1 -0.36
30 - 34 0.6 0.7 0.01 Medical history: Cardiovascular disease
35 - 39 0.3 1.1 0.10 Atrial fibrillation 33.4 26.0 -0.16
40 - 44 1.0 0.9 -0.01 Cerebrovascular disease 13.3 9.7 -0.11
45 - 49 2.3 2.2 -0.01 Coronary arteriosclerosis 39.6 29.7 -0.21
50 - 54 2.2 2.8 0.04 Heart disease 72.6 58.2 -0.31
55 - 59 2.9 3.2 0.02 Heart failure 29.3 24.2 -0.12
60 - 64 3.0 5.4 0.12 Ischemic heart disease 18.6 14.6 -0.11
65 - 69 17.0 16.2 -0.02 Peripheral vascular disease 40.5 27.4 -0.28
70 - 74 18.8 19.2 0.01 Pulmonary embolism 3.3 2.8 -0.03
75 - 79 19.1 16.4 -0.07 Venous thrombosis 11.0 7.1 -0.14
80 - 84 15.3 14.6 -0.02 Medical history: Neoplasms
85 - 89 11.8 10.3 -0.05 Hematologic neoplasm 12.2 7.8 -0.15
90 - 94 2.9 3.4 0.03 Malignant lymphoma 4.4 3.6 -0.04
95 - 99 1.6 2.8 0.08 Malignant neoplasm of anorectum 2.6 1.7 -0.06
100 - 104 0.7 0.4 -0.04 Malignant neoplastic disease 39.7 26.9 -0.27
Gender: female 55.2 57.5 0.05 Malignant tumor of breast 5.7 3.3 -0.12
Medical history: General Malignant tumor of colon 5.5 3.4 -0.10
Acute respiratory disease 25.5 19.5 -0.14 Malignant tumor of lung 4.6 3.7 -0.05
Attention deficit hyperactivity disorder 0.3 0.6 0.04 Malignant tumor of urinary bladder 4.5 3.3 -0.06
Chronic liver disease 3.5 3.0 -0.03 Medication use
Chronic obstructive lung disease 11.5 8.1 -0.11 Agents acting on the renin-angiotensin system 43.1 0 -1.23
Crohn’s disease 1.0 0.7 -0.03 Antibacterials for systemic use 34.6 0 -1.03
Dementia 14.3 11.2 -0.09 Antidepressants 35.6 0 -1.05
Depressive disorder 11.1 8.5 -0.09 Antiepileptics 17.6 0 -0.65
Diabetes mellitus 66.8 48.3 -0.38 Antiinflammatory and antirheumatic products 23.2 0 -0.78
Gastroesophageal reflux disease 19.6 12.9 -0.18 Antineoplastic agents 12.7 0 -0.54
Gastrointestinal hemorrhage 8.4 5.7 -0.11 Antipsoriatics 0.4 0 -0.09
Human immunodeficiency virus infection 0.4 0.5 0.01 Antithrombotic agents 32.9 0 -0.99
Hyperlipidemia 33.6 24.3 -0.21 Beta blocking agents 36.7 0 -1.08
Hypertensive disorder 4.9 4.9 0.00 Calcium channel blockers 27.7 0 -0.88
Lesion of liver 4.1 4.1 0.00 Diuretics 40.2 0 -1.16
Obesity 7.2 5.7 -0.06 Drugs for acid related disorders 25.1 0 -0.82
Osteoarthritis 55.0 39.2 -0.32 Drugs for obstructive airway diseases 21.2 0 -0.73
Pneumonia 5.9 4.6 -0.06 Drugs used in diabetes 30.8 0 -0.94
Psoriasis 2.5 0.6 -0.15 Immunosuppressants 4.6 0 -0.31
Renal impairment 26.9 21.5 -0.13 Lipid modifying agents 42.5 0 -1.22
Rheumatoid arthritis 9.3 5.0 -0.17 Opioids 22.1 0 -0.75
Schizophrenia 4.6 4.4 -0.01 Psycholeptics 32.9 0 -0.99
Ulcerative colitis 0.7 0.2 -0.07 Psychostimulants, agents used for adhd and nootropics 7.3 0 -0.40
Urinary tract infectious disease 27.6 21.0 -0.15 
## Drug vs. All ##
Characteristic % (n = 1,000) % (n = 1,000) Std.Diff Characteristic % (n = 1,000) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 1.9 1.4 -0.04
25 - 29 0.5 0.4 -0.01 Visual system disorder 47.6 30.1 -0.36
30 - 34 0.6 0.7 0.01 Medical history: Cardiovascular disease
35 - 39 0.3 1.1 0.10 Atrial fibrillation 33.4 26.0 -0.16
40 - 44 1.0 0.9 -0.01 Cerebrovascular disease 13.3 9.7 -0.11
45 - 49 2.3 2.2 -0.01 Coronary arteriosclerosis 39.6 29.7 -0.21
50 - 54 2.2 2.8 0.04 Heart disease 72.6 58.2 -0.31
55 - 59 2.9 3.2 0.02 Heart failure 29.3 24.2 -0.12
60 - 64 3.0 5.4 0.12 Ischemic heart disease 18.6 14.6 -0.11
65 - 69 17.0 16.2 -0.02 Peripheral vascular disease 40.5 27.4 -0.28
70 - 74 18.8 19.2 0.01 Pulmonary embolism 3.3 2.8 -0.03
75 - 79 19.1 16.4 -0.07 Venous thrombosis 11.0 7.1 -0.14
80 - 84 15.3 14.6 -0.02 Medical history: Neoplasms
85 - 89 11.8 10.3 -0.05 Hematologic neoplasm 12.2 7.8 -0.15
90 - 94 2.9 3.4 0.03 Malignant lymphoma 4.4 3.6 -0.04
95 - 99 1.6 2.8 0.08 Malignant neoplasm of anorectum 2.6 1.7 -0.06
100 - 104 0.7 0.4 -0.04 Malignant neoplastic disease 39.7 26.9 -0.27
Gender: female 55.2 57.5 0.05 Malignant tumor of breast 5.7 3.3 -0.12
Medical history: General Malignant tumor of colon 5.5 3.4 -0.10
Acute respiratory disease 25.5 19.5 -0.14 Malignant tumor of lung 4.6 3.7 -0.05
Attention deficit hyperactivity disorder 0.3 0.6 0.04 Malignant tumor of urinary bladder 4.5 3.3 -0.06
Chronic liver disease 3.5 3.0 -0.03 Medication use
Chronic obstructive lung disease 11.5 8.1 -0.11 Agents acting on the renin-angiotensin system 43.1 0 -1.23
Crohn’s disease 1.0 0.7 -0.03 Antibacterials for systemic use 34.6 0 -1.03
Dementia 14.3 11.2 -0.09 Antidepressants 35.6 0 -1.05
Depressive disorder 11.1 8.5 -0.09 Antiepileptics 17.6 0 -0.65
Diabetes mellitus 66.8 48.3 -0.38 Antiinflammatory and antirheumatic products 23.2 0 -0.78
Gastroesophageal reflux disease 19.6 12.9 -0.18 Antineoplastic agents 12.7 0 -0.54
Gastrointestinal hemorrhage 8.4 5.7 -0.11 Antipsoriatics 0.4 0 -0.09
Human immunodeficiency virus infection 0.4 0.5 0.01 Antithrombotic agents 32.9 0 -0.99
Hyperlipidemia 33.6 24.3 -0.21 Beta blocking agents 36.7 0 -1.08
Hypertensive disorder 4.9 4.9 0.00 Calcium channel blockers 27.7 0 -0.88
Lesion of liver 4.1 4.1 0.00 Diuretics 40.2 0 -1.16
Obesity 7.2 5.7 -0.06 Drugs for acid related disorders 25.1 0 -0.82
Osteoarthritis 55.0 39.2 -0.32 Drugs for obstructive airway diseases 21.2 0 -0.73
Pneumonia 5.9 4.6 -0.06 Drugs used in diabetes 30.8 0 -0.94
Psoriasis 2.5 0.6 -0.15 Immunosuppressants 4.6 0 -0.31
Renal impairment 26.9 21.5 -0.13 Lipid modifying agents 42.5 0 -1.22
Rheumatoid arthritis 9.3 5.0 -0.17 Opioids 22.1 0 -0.75
Schizophrenia 4.6 4.4 -0.01 Psycholeptics 32.9 0 -0.99
Ulcerative colitis 0.7 0.2 -0.07 Psychostimulants, agents used for adhd and nootropics 7.3 0 -0.40
Urinary tract infectious disease 27.6 21.0 -0.15 
## Top drugs and conditions for DEC ##
drugs_180_days n_180_days
beta blocking agents 394
antithrombotic agents 352
nervous system 304
cardiovascular system 293
alimentary tract and metabolism 291
respiratory system 249
blood and blood forming organs 239
antiepileptics 224
sensory organs 223
all other therapeutic products 222
ophthalmologicals 222
lipid modifying agents 221
lipid modifying agents, plain 221
systemic hormonal preparations, excl. sex hormones and insulins 215
analgesics 214
diuretics 214
agents acting on the renin-angiotensin system 212
antiinfectives for systemic use 203
stomatological preparations 200
psychoanaleptics 199
antihistamines for systemic use 198
hmg coa reductase inhibitors 192
psycholeptics 191
musculo-skeletal system 189
antibacterials for systemic use 185
cond_180_days n_180_days
inflammation of specific body systems 312
inflammation of specific body organs 305
pain 301
pain finding at anatomical site 301
heart disease 296
arthropathy 290
vascular disorder 266
diabetes mellitus 256
measurement finding outside reference range 256
soft tissue lesion 251
pain of truncal structure 247
type 2 diabetes mellitus 243
neoplastic disease 230
structural disorder of heart 214
cardiac arrhythmia 213
degenerative disorder of musculoskeletal system 197
osteoarthritis 196
abnormal blood cell count 194
arteriosclerotic vascular disease 189
measurement finding below reference range 188
anemia 183
cytopenia 183
erythropenia 183
hemoglobin level outside reference range 183
hemoglobin low 183